跳至主要内容
临床试验/JPRN-jRCTc030200090
JPRN-jRCTc030200090暂停1 期

A clinical study on the immunological effect of the preventive immune-cell therapy (gdT) against high risk group of cancer

Takimoto Rishu0 个研究点目标入组 20 人开始时间: 2020年8月20日最近更新:

试验速览

阶段
1 期
状态
暂停
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • (1)Have risk factors for cancer and desire for receiving the preemptive immune-cell therapy.
  • (2)Be > 20 of age when obtaining the informed consent.
  • (3)Be determined to be appropriate by the doctor in charge.
  • (4)Provide written informed consent.

排除标准

  • (1)Be diagnosed with cancer.
  • (2)Desire to receive the immune-cell therapy for the treatment of any allergic disease.
  • (3)Be HIV or HTLV-1 positive.
  • (4)Be an allotransplant recipient.
  • (5)Have a history or sign of interstitial pneumonia.
  • (6)Have an active autoimmune disease.
  • (7)Be a female who is pregnant, nursing, or of childbearing potential.
  • (8)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study.
  • (9)Be determined to be inappropriate by the doctor in charge.

研究者

发起方
Takimoto Rishu

相似试验